Skip to main content
. 2020 Nov 4;42(7):1180–1189. doi: 10.1038/s41401-020-00546-8

Fig. 1. AXL is a potential therapeutic target for the treatment of ovarian cancer.

Fig. 1

a GEO2R analysis comparing differences in AXL mRNA expression levels between normal ovarian epithelial tissue and OvCa tissue in GSE14407. b The levels of AXL mRNA between OvCa tissues and normal ovarian tissues were determined by qRT-PCR. Actin served as a loading control. c The effect of AXL mRNA levels on the overall survival of OvCa patients was analyzed in the GSE9891 dataset. d The expression of AXL protein in the normal ovarian epithelial cell line and OvCa cell lines was measured by Western blot analysis. Actin served as a loading control. e The cell proliferation of HO-8910 and SKOV3.ip cells stably transfected with shAXL or treated with 1 μM R428 was measured by the CCK-8 assay. f Cell proliferation was measured by a colony formation assay in SKOV3.ip cells transfected with AXL shRNA. g SKOV3.ip-shNT and SKOV3.ip-shAXL cells were plated in 0.7% agar. After 14 days, colonies were photographed and quantified. **P < 0.01.